IQVIA Holdings' (NYSE:IQV) Five-year Earnings Growth Trails the Favorable Shareholder Returns
IQVIA Holdings Inc. (NYSE:IQV) Delivered A Better ROE Than Its Industry
IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024
S&P 500 Futures Steady In Premarket Trading; United Therapeutics, Tempus AI Lead
Looking Into IQVIA Hldgs's Recent Short Interest
Medicare's Negotiated Drug Prices Will Save Taxpayers $6 Billion in First Year, White House Says
US Drug Price Measure to Cut Costs by US$7.5b in 2026
Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 40%?
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
Home Depot To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday
JP Morgan Maintains Overweight on IQVIA Hldgs, Raises Price Target to $288
IQVIA Hldgs Analyst Ratings
Does IQVIA Holdings (NYSE:IQV) Deserve A Spot On Your Watchlist?
Express News | IQVIA Holdings Inc : JP Morgan Raises Target Price to $288 From $260
Express News | Morgan Stanley Wealth Management Removes Position in Halliburton Co
Express News | Morgan Stanley Wealth Management Increases Internally Held Portfolio Weights in Spotify Technology, Pinterest, Chewy
Express News | Morgan Stanley Wealth Management Removes Position in S&P Global Inc
Express News | Morgan Stanley Wealth Management Reduces Position in Iqivia Holdings Inc
Express News | Morgan Stanley Wealth Management Increases Position in Nvidia Corp
Express News | Morgan Stanley Wealth Management Adds Position in Teradyne Inc
No Data